
FGHQF
Healthcare · Biotechnology · $356.0M market cap
$0.17500.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2021 | Time not confirmed | 0.00 | 0.00 | — |
| Mar 29, 2021 | Before the open | 0.00 | 0.00 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | 0.00 | — |
| Aug 28, 2020 | Before the open | 0.00 | 0.00 | — |
| Jun 26, 2020 | After the close | 0.00 | 0.00 | — |
| Mar 30, 2020 | Before the open | 0.00 | 0.00 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | 0.00 | — |
| Aug 20, 2019 | Before the open | 0.00 | 0.00 | — |
| May 17, 2019 | After the close | 0.00 | 0.00 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | 0.00 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | 0.00 | — |
| Sep 30, 2018 | Time not confirmed | 0.00 | 0.00 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | 0.00 | — |
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug…
| Mar 31, 2018 |
| Time not confirmed |
| 0.00 |
| 0.00 |
| — |